Insider · CIK 0001949621
Joshua M Eizen
Files at ANTX (AN2 Therapeutics, Inc.). First filing Jan 7, 2025, latest Jul 10, 2026.
In brief
Joshua M Eizen files SEC Form 4 as officer at ANTX (AN2 Therapeutics, Inc.). Since Jan 7, 2025, Joshua M Eizen has reported 0 open-market buys worth $0 and 4 open-market sells worth $66k, the latest filed on Jul 10, 2026.
A track record needs three past buys with six months of prices behind them; Joshua M Eizen has 0, so none is measured yet.
The newest scored trade: sold $25k of ANTX on Jul 8, 2026, filed Jul 10, 2026, scored 15 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $53k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | $25k 5,945 shares | -3% | +328% from low-19% from high | |
| 35Weak | AN2 Therapeutics, Inc. | $25k 24,854 shares | -14% | +2% from low-30% from high | |
| 23Weak | AN2 Therapeutics, Inc. | $3,214 2,819 shares | -2% | +14% from low-32% from high | |
| 30Weak | AN2 Therapeutics, Inc. | $13k 9,663 shares | -8% | +42% from low-15% from high |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -5,945 | $4.17 | $25k | 206,554 | Jul 10, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +92,000 | - | - | 92,000 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -92,000 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +50,150 | - | - | 50,150 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -50,150 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 207,499 | Feb 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 23, 2026 |
| Jan 5, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -17,923 | $1.00 | $18k | 159,430 | Jan 7, 2026 |
| Jan 6, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -6,931 | $1.01 | $7,014 | 152,499 | Jan 7, 2026 |
| Nov 4, 2025 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -2,819 | $1.14 | $3,214 | 177,353 | Nov 6, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +58,500 | $0.00 | $0 | 175,172 | Feb 28, 2025 |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +117,000 | $0.00 | $0 | 117,000 | Feb 28, 2025 |
| Jan 3, 2025 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stock | -9,663 | $1.34 | $13k | 116,672 | Jan 7, 2025 |
| Nov 4, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +31,500 | $0.00 | $0 | 126,335 | Nov 5, 2024 |
| Nov 4, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +63,000 | $0.00 | $0 | 63,000 | Nov 5, 2024 |
| Mar 15, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 32,447 | Mar 18, 2024 |
| Mar 15, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 18, 2024 |
Questions about Joshua M Eizen
Answered from the filings on this page, as of the latest one.
Is Joshua M Eizen buying or selling?
In the last 12 months Joshua M Eizen reported 0 open-market buys worth $0 and 3 open-market sells worth $53k on SEC Form 4; the latest was sold $25k of ANTX on Jul 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Joshua M Eizen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joshua M Eizen has 0.
Where does Joshua M Eizen file Form 4?
Joshua M Eizen has filed Form 4 at ANTX (AN2 Therapeutics, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.